Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

.2001 Apr 10;98(8):4652-7.
doi: 10.1073/pnas.061034298. Epub 2001 Mar 20.

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity

Affiliations

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity

P D Lambert et al. Proc Natl Acad Sci U S A..

Abstract

Ciliary Neurotrophic Factor (CNTF) was first characterized as a trophic factor for motor neurons in the ciliary ganglion and spinal cord, leading to its evaluation in humans suffering from motor neuron disease. In these trials, CNTF caused unexpected and substantial weight loss, raising concerns that it might produce cachectic-like effects. Countering this possibility was the suggestion that CNTF was working via a leptin-like mechanism to cause weight loss, based on the findings that CNTF acts via receptors that are not only related to leptin receptors, but also similarly distributed within hypothalamic nuclei involved in feeding. However, although CNTF mimics the ability of leptin to cause fat loss in mice that are obese because of genetic deficiency of leptin (ob/ob mice), CNTF is also effective in diet-induced obesity models that are more representative of human obesity, and which are resistant to leptin. This discordance again raised the possibility that CNTF might be acting via nonleptin pathways, perhaps more analogous to those activated by cachectic cytokines. Arguing strongly against this possibility, we now show that CNTF can activate hypothalamic leptin-like pathways in diet-induced obesity models unresponsive to leptin, that CNTF improves prediabetic parameters in these models, and that CNTF acts very differently than the prototypical cachectic cytokine, IL-1. Further analyses of hypothalamic signaling reveals that CNTF can suppress food intake without triggering hunger signals or associated stress responses that are otherwise associated with food deprivation; thus, unlike forced dieting, cessation of CNTF treatment does not result in binge overeating and immediate rebound weight gain.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment with leptin or CNTFAx15 in ob/ob and DIO mice[starting body weight ≈50 g]. Groups of ob/ob mice(n = 8) or DIO mice (n = 7)received a daily s.c. injection of vehicle (V), leptin (L; 1mg/kg/day), or CNTFAx15 (C; 0.03, 0.1, 0.3mg/kg/day). Body weight was measured daily and is shown as thepercentage difference from body weight on the first day of injection(A1 andB1). A 24-h food intake was recordedand is shown as percentage of vehicle-treated control(A2 andB2). Body compositions were determinedby carcass analysis at the end of the study, and data are shown asdifference in fat and lean body mass (LBM) relative to vehicle-treatedcontrols (A3 andB3). All data are mean ± SEM.
Figure 2
Figure 2
pSTAT3 and COX-2 immunostaining in the brain of ob/ob and DIO mice.The ob/ob mice (A) exhibited nuclear pSTAT3immunostaining in neurons of the arcuate nucleus (arrowheads) 30 minafter i.v. treatment with CNTFAx15 (0.1 mg/kg) or leptin(1.0 mg/kg). However, DIO mice showed STAT3-phosphorylation inresponse to CNTFAx15 but not leptin (B). NopSTAT immunostaining was seen in the arcuate nucleus of ob/ob(A) or DIO (B) mice 30 min after i.v.treatment with a dose of IL-1 (0.01 mg/kg) known to reduce bodyweight. Note that CNTFAx15 also induced pSTAT3 expressionin the median eminence and in tanycytes and ependyma of the ventralpart of the third ventricle. STAT3-phosphorylation was also notedwithin and adjacent to other circumventricular organs (area postrema,subfornical organ, and organum vasculosum of the lamina terminalis),which contain a fenestrated vasculature (data not shown). However,pSTAT3-immunoreactivity was not evident in other areas of the brainwhere CNTF receptor α is equally abundant, suggesting thatperipherally administered CNTFAx15 does not freely crossthe blood–brain barrier. The cortex of DIO mice (C)exhibited COX-2-immunostaining in blood vessels (arrowheads) 6 hafter i.v. administration of IL-1 (0.01 mg/kg) but notCNTFAx15 (0.1 mg/kg). Arc, arcuate nucleus.
Figure 3
Figure 3
Evaluation of CTA, expressed as percentage of fluid intake as waterafter administration of CNTFAx15 (0.1, 0.5 mg/kg) or IL-1(0.03 mg/kg) in C57BL/6 mice (n = 6,A).B illustrates changes in tibialisanterior (TA) muscle mass following a 10% reduction in body weightinduced by CNTFAx15, IL-1, or food restriction(n = 5,B) in C57BL/6 mice(starting BW ≈24 g). The percentage difference in TA muscle weightfrom control (closed bar) is plotted alongside percentage change inbody weight from day 0 to day 3 (open bar). Equivalent changes wereobserved in the relative weights of other muscles. Similarly distincteffects of IL-1 and CNTFAx15 on CTA response and musclemass also were observed in AKR mice (data not shown).
Figure 4
Figure 4
Effect of CNTFAx15 and pair-feeding on hypothalamic markersof hunger in C57BL6 mice. Digitized images of pCREB immunostaining inthe PVN after 3 days of s.c. treatment with vehicle,CNTFAx15 (C, 0.3 mg/kg/day) or pair-feeding(A). 3v, third ventricle. Histograms show meannumber of pCREB-immunoreactive cells and NPY immunoreactivity(percentage of vehicle group) in the PVN after treatment(B andC;n =4). ANOVA: pCREB,P < 0.01; NPY,P = 0.01. †, Difference from vehicle (veh); #,difference from pair-fed by Dunnett post hoc test. Northern blotanalysis for Agrp, NPY, and glyceraldehyde-3-phosphate dehydrogenase(GAPDH) mRNA from hypothalamus of AKR mice after 4 days of treatmentwith CNTFAx15 (0.3 mg/kg/day), pair-feeding or a48 h fast also is shown (D). Each lane representspooled tissue from three mice.
Figure 5
Figure 5
Lack of rebound food intake in DIO mice after cessation of dailys.c. injection with CNTFAx15. DIO mice(n = 7; starting BW ≈50 g) were treated for 3(A1 andB1) or 7 days(A2 andB2) with vehicle (V) orCNTFAx15 (C, 0.1, 0.3 mg/kg/day), or were pair-fed tothe food intake of CNTFAx15-treated mice (P) after whichall treatment was stopped and all animals were returned to ad libfeeding. The 24-h food intake (A1 andA2) and change in body weight(percentage from day 0;B1 andB2) was measured throughout bothstudies. The overeating and rapid return to prerestriction body weightseen after returning pair-fed mice to ad lib feeding was not seen aftercessation of treatment with CNTFAx15.
See this image and copyright information in PMC

Comment in

References

    1. Lin L, Armes L, Sommer A, Smith D, Collins F. J Biol Chem. 1990;265:8942–8947. - PubMed
    1. Sendtner M, Arakawa Y, Stockli K, Kreutzberg G, Thoenen H. J Cell Sci Suppl. 1991;15:103–109. - PubMed
    1. Amyotrophic Lateral Sclerosis CNTF Treatment Study Group. Neurology. 1996;46:1244–1249. - PubMed
    1. Chen H, Charlat O, Tartaglia L A, Woolf E A, Weng X, Ellis S J, Lakey N D, Culpepper J, Moore K J, Breitbart R E, et al. Cell. 1996;84:491–495. - PubMed
    1. Tartaglia L A, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards G J, Campfield L A, Clark F T, Deeds J, et al. Cell. 1995;83:1263–1271. - PubMed

MeSH terms

Substances

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2026 Movatter.jp